Clinical Use and Adverse Drug Reactions of Linezolid: A Retrospective Study in Four Belgian Hospital Centers.
adverse drug reaction
anemia
lactic acidosis
linezolid
neuropathy
off label use
serotonin syndrome
thrombocytopenia
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
04 May 2021
04 May 2021
Historique:
received:
19
04
2021
revised:
29
04
2021
accepted:
29
04
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
In Belgium, linezolid is indicated for pneumonia and skin and soft tissue infections, but is more broadly used, due to its oral bioavailability and activity against multiresistant organisms. This could increase the risk of adverse drug reactions (ADR), notably hematological disorders (anemia, thrombocytopenia), neuropathy, or lactic acidosis. We analyzed linezolid clinical use in relationship with occurrence of ADR in Belgian hospitals and highlighted risk factors associated with the development of thrombocytopenia. A retrospective analysis of electronic medical records and laboratory tests of adult patients treated with linezolid in four Belgian hospitals in 2016 allowed the collection of ADR for 248 linezolid treatments. Only 19.7% of indications were in-label. ADR included 43 thrombocytopenia, 17 anemia, 4 neuropathies, and 4 increases in lactatemia. In a multi-variate analysis, risk factors of thrombocytopenia were a treatment duration > 10 days, a glomerular filtration rate < 60 mL/min, and a Charlson index ≥ 4. Off-label use of linezolid is frequent in Belgium, and ADR more frequent than reported in the summary of product characteristics, but not statistically associated with any indication. This high prevalence of ADR could be related to a high proportion of patients presenting risk factors in our population, highlighting the importance of detecting them prospectively.
Identifiants
pubmed: 34064418
pii: antibiotics10050530
doi: 10.3390/antibiotics10050530
pmc: PMC8147790
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Infection. 2014 Dec;42(6):1007-12
pubmed: 25119433
J Clin Pharm Ther. 2015 Jun;40(3):279-84
pubmed: 25732525
Int J Clin Pharm. 2014 Aug;36(4):795-9
pubmed: 24913359
JAMA Intern Med. 2016 Jan;176(1):55-63
pubmed: 26523731
Eur Respir J. 2012 Dec;40(6):1430-42
pubmed: 22496332
Farm Hosp. 2019 Mar 01;43(2):61-65
pubmed: 30848179
Can J Hosp Pharm. 2019 Mar-Apr;72(2):133-138
pubmed: 31036974
Expert Rev Anti Infect Ther. 2012 Dec;10(12):1383-92
pubmed: 23253317
Infection. 2004 Feb;32(1):8-14
pubmed: 15007736
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12150-12155
pubmed: 27791002
J Antimicrob Chemother. 2006 Aug;58(2):273-80
pubmed: 16735427
J Antimicrob Chemother. 2003 May;51 Suppl 2:ii45-53
pubmed: 12730142
Diagn Microbiol Infect Dis. 2014 May;79(1):93-7
pubmed: 24565849
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
Eur J Clin Microbiol Infect Dis. 2017 Jul;36(7):1133-1141
pubmed: 28127641
Int J Clin Pharm. 2014 Oct;36(5):1059-68
pubmed: 25135806
Int J Antimicrob Agents. 2016 Jun;47(6):490-4
pubmed: 27208900
Farm Hosp. 2011 Nov-Dec;35(6):322-5
pubmed: 22035598
J Antimicrob Chemother. 2013 Sep;68(9):2128-33
pubmed: 23625638
Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):303-308
pubmed: 28419737
Ann Pharmacother. 2013 Mar;47(3):388-97
pubmed: 23424229
Clin Pharmacokinet. 2003;42(13):1129-40
pubmed: 14531724
BMJ. 2014 Feb 19;348:g1626
pubmed: 24554467
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Iran J Pharm Res. 2015 Summer;14(3):857-64
pubmed: 26330874
Int J Infect Dis. 2015 Feb;31:47-52
pubmed: 25499040
Curr Opin Infect Dis. 2015 Apr;28(2):117-24
pubmed: 25692274
Eur J Clin Microbiol Infect Dis. 2017 Aug;36(8):1511-1517
pubmed: 28343274
JAMA Intern Med. 2017 Sep 1;177(9):1308-1315
pubmed: 28604925
Expert Opin Pharmacother. 2007 Oct;8(14):2381-400
pubmed: 17927491
Medicine (Baltimore). 2018 Sep;97(36):e12114
pubmed: 30200095
Int J Antimicrob Agents. 2015 Dec;46(6):727-8
pubmed: 26526894
Eur J Clin Microbiol Infect Dis. 2014 Jun;33(6):1029-35
pubmed: 24515096
Hosp Pract (1995). 2010 Apr;38(2):19-28
pubmed: 20469610
J Antimicrob Chemother. 2012 Aug;67(8):2034-42
pubmed: 22553142
Ann Pharmacother. 2018 Nov;52(11):1162-1164
pubmed: 29911390
J Infect Chemother. 2016 Aug;22(8):536-42
pubmed: 27321773
Clin Infect Dis. 2011 Feb 1;52(3):e18-55
pubmed: 21208910
Handb Clin Neurol. 2013;115:729-42
pubmed: 23931812
Antimicrob Agents Chemother. 2003 Jun;47(6):1824-31
pubmed: 12760854